Western Oncolytics Awarded SBIR Grant to Fund the Company's Next Generation Oncolytic Virus Therapy

Tuesday, May 21, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

PITTSBURGH, May 21, 2019 /PRNewswire/ -- Western Oncolytics (WO), a privately held biotechnology company focused on the discovery and development of next generation oncolytic vaccinia virus immunotherapies announced that it was awarded a Small Business Innovation Research (SBIR) Grant. SBIR grants are coordinated by the Small Business Administration of the U.S. Government and require

candidates to undergo a rigorous approval process.

"Given that we believe this was highly competitive, we are very pleased to have been awarded this grant, which will be applied toward advancing our lead clinical candidate, WO-VET-S3, into the clinic," stated Stephen H. Thorne, Ph.D., WO's founder and chief scientific officer. "This award validates both the novelty and the clinical potential of this therapeutic approach."

About the Multi-Mechanistic VET Platform StrategyOncolytic virus development has progressed from basic deletions for conditional tumor replication to multiple modifications acting in various mechanisms to enhance efficacy. WO's proprietary platform, VET (vaccinia-enhanced template), incorporates multiple modifications to enhance tumor selectivity, systemic delivery, replication potency and antitumor immunity. WO-VET-S3, derived from the VET platform, expresses a STAT3 inhibitor. STAT3, an important immune suppressor and regulator of tumor growth and metastases, is found to be overactive in many cancers and is known to be a strong predictor of poor prognosis. WO expects to initiate clinical studies for WO-VET-S3 in 2020.

About Western OncolyticsWestern Oncolytics, a privately held biotechnology company, is developing a new generation of optimized, multi-mechanistic cancer immunotherapies. The company's oncolytic vaccinia virus immunotherapies are designed with proprietary, synergistic combinations of genetic modifications to systemically target and destroy cancer cells while enhancing patients' anti-tumor immune response. Western Oncolytics is committed to creating a best-in-class immuno-oncology platform to help patients across the globe beat cancer. For additional information, please visit www.westernoncolytics.com.

Contact:                          Jennifer WilliamsCook Williams Communications, Inc.Investor and Media Relations360.668.3701jennifer@cwcomm.org

 

Cision View original content:http://www.prnewswire.com/news-releases/western-oncolytics-awarded-sbir-grant-to-fund-the-companys-next-generation-oncolytic-virus-therapy-300853777.html

SOURCE Western Oncolytics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store